Keyword

aprepitant

Description: A neurokinin-1 receptor antagonist medication used to prevent nausea and vomiting, particularly those associated with chemotherapy.

Primary topic: Nausea and vomiting management (58%)

Wikidata ID: wiki/Q621834

OpenAlex ID: keywords/aprepitant

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

2011 · Ethan Basch, Ann Alexis Prestrud, et al. · Journal of Clinical Oncology · 1,060

PDF

The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group

2003 · Paul J. Hesketh, Steven M. Grunberg, et al. · Journal of Clinical Oncology · 779

American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006

2006 · Mark G. Kris, Paul J. Hesketh, et al. · Journal of Clinical Oncology · 740

PDF

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting

2003 · Sergio Poli‐Bigelli, Jose Rodrigues‐Pereira, et al. · Cancer · 564

Antiemetics: ASCO Guideline Update

2020 · Paul J. Hesketh, Mark G. Kris, et al. · Journal of Clinical Oncology · 476

Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy

2005 · David G. Warr, Paul J. Hesketh, et al. · Journal of Clinical Oncology · 463

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting

2016 · Rudolph M. Navari, Rui Qin, et al. · New England Journal of Medicine · 453

PDF

Olanzapine Versus Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Randomized Phase III Trial

2011 · Rudolph M. Navari, Sarah E. Gray, et al. · The Journal of Supportive Oncology · 319

Targeting the Neurokinin Receptor 1 with Aprepitant: A Novel Antipruritic Strategy

2010 · Sonja Ständer, Dorothee Siepmann, et al. · PLoS ONE · 293

PDF

Lack of Efficacy of the Substance P (Neurokinin1 Receptor) Antagonist Aprepitant in the Treatment of Major Depressive Disorder

2005 · Martin Keller, Stuart Montgomery, et al. · Biological Psychiatry · 286

Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis

2020 · Stephanie Weibel, Gerta Rücker, et al. · Cochrane Database of Systematic Reviews · 279

The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human

2004 · Yunhui Wu, Alice Loper, et al. · International Journal of Pharmaceutics · 275

Postoperative nausea and vomiting: A simple yet complex problem

2016 · D Nagarekha, SafiyaImtiaz Shaikh, et al. · Anesthesia Essays and Researches · 262

Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression

2003 · Mark S Kramer, Andrew Winokur, et al. · Neuropsychopharmacology · 256

Gastroparesis: a turning point in understanding and treatment

2019 · Madhusudan Grover, Gianrico Farrugia, et al. · Gut · 254

Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists

2003 · P.J. Hesketh, S. Van Belle, et al. · European Journal of Cancer · 247

TRPA1 controls inflammation and pruritogen responses in allergic contact dermatitis

2013 · Boyi Liu, Jasmine Escalera, et al. · The FASEB Journal · 232

Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment

2006 · H.J. Schmoll, M.S. Aapro, et al. · Annals of Oncology · 232

Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

2019 · Hironobu Hashimoto, Masakazu Abe, et al. · The Lancet Oncology · 231

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study

2009 · Bernardo L. Rapoport, Karin Jordan, et al. · Supportive Care in Cancer · 229

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study

2014 · P.J. Hesketh, G. Rossi, et al. · Annals of Oncology · 228

PDF

Biological and Pharmacological Aspects of the NK1-Receptor

2015 · Susana Garcia-Recio, Pedro Gascón · BioMed Research International · 227

PDF

A Randomized, Double-Blind Comparison of the NK1 Antagonist, Aprepitant, Versus Ondansetron for the Prevention of Postoperative Nausea and Vomiting

2007 · Tong J. Gan, Christian C. Apfel, et al. · Anesthesia & Analgesia · 225

Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE

2011 · Steven Grunberg, Daniel Chua, et al. · Journal of Clinical Oncology · 217

Establishing the dose of the oral NK 1 antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomiting

2003 · Sant P. Chawla, Steven M. Grunberg, et al. · Cancer · 217

PDF

Works count: 2,681

Citation count: 42,260